Simulations Plus Announces Proposed Underwritten Public Offering
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.
All of the shares of common stock to be sold in the offering will be offered by Simulations Plus. In addition, Simulations Plus expects to grant the underwriters of the offering a 30-day option to purchase additional shares of its common stock offered in the public market. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Oppenheimer & Co. Inc. and Raymond James & Associates, Inc. are acting as joint book-running managers for the offering.
Simulations Plus intends to use the net proceeds from the offering for strategic mergers and acquisitions, although Simulations Plus has no present commitments or agreements to enter into any such mergers or acquisitions, working capital requirements and other general corporate purposes, including investing in enhanced information and accounting systems, and personnel in support of corporate growth.
This offering is being made pursuant to an automatic shelf registration statement on Form S-3 (No. 333-239770), which was previously filed with the Securities and Exchange Commission (“SEC”) on July 9, 2020, which became automatically effective. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at https://www.sec.gov, or by contacting Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad St., 26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at EquityProspectus@opco.com; or Raymond James & Associates, Inc., Attention: Syndicate Department, 880 Carillon Parkway, St. Petersburg, FL 33716, by telephone at (800) 248-8863 or by email at firstname.lastname@example.org. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.